肿瘤细胞PD-L1表达与高危子宫内膜癌良好预后相关
该研究纳入833例子宫内膜癌患者(约半数高危),按分子分型(POLE超突变、MMR缺陷、p53突变、NSMP)分层,用免疫组化检测肿瘤细胞(TC)和免疫细胞(IC)的PD-L1表达及联合阳性评分(CPS)。结果显示TC、IC及CPS阳性率分别为14.0%、37.3%、45.1%,TC PD-L1阳性在高危患者中与良好预后相关,而IC或CPS无此关联。
要点
- TC PD-L1阳性(≥1%)见于14.0%样本,IC阳性37.3%,CPS≥1为45.1%。
- TC PD-L1阳性在高危子宫内膜癌中与良好预后相关,IC或CPS无此关联。
- PD-L1在TC和IC中的分布及预后意义不同,分别评估可能更利于免疫治疗选例。
核心结论
- 肿瘤细胞PD-L1阳性与高危子宫内膜癌良好预后相关,而免疫细胞或CPS无此关联。
- TC与IC的PD-L1分布和预后意义不同,分别评估可能比CPS更适用于免疫治疗患者选择。
研究设计与样本
- 回顾性队列研究,纳入833例子宫内膜癌患者,约半数高危。
- 采用POLE外切酶域直接测序、MMR蛋白(MLH1、PMS2、MSH2、MSH6)和p53免疫组化进行分子分型。
- PD-L1通过免疫组化在肿瘤细胞和免疫细胞中分别评估,并计算联合阳性评分(CPS)。
主要发现
- TC PD-L1阳性(≥1%)、IC阳性(≥1%)和CPS≥1的检出率分别为14.0%、37.3%和45.1%。
- TC PD-L1阳性在高级别肿瘤中比低级别更常见。
- IC PD-L1阳性与淋巴血管间隙浸润、非子宫内膜样组织学类型和深肌层浸润相关。
- TC和IC的PD-L1表达在POLE超突变和MMR缺陷亚型中比p53突变和NSMP亚型更常见。
- TC PD-L1阳性(而非IC或CPS)在高危子宫内膜癌患者中与良好预后相关。
关键数值与推荐
- PD-L1阳性阈值:TC≥1%、IC≥1%、CPS≥1。
- 分子分型:POLE超突变、MMR缺陷、p53突变、非特异性分子谱(NSMP)。
临床怎么用
- 在高危子宫内膜癌中,应分别评估肿瘤细胞和免疫细胞的PD-L1表达,而非仅依赖CPS。
- TC PD-L1阳性可作为高危患者预后良好的参考指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate programmed cell death ligand 1 (PD-L1) expression patterns and define the associations among PD-L1, molecular subtypes, pathological features, and survival in a cohort of 833 patients with endometrial cancer, of whom approximately half had high-risk disease. METHODS: Using direct sequencing of the polymerase epsilon (POLE) exonuclease domain as well as immunohistochemistry for mismatch repair (MMR) proteins (MLH1, PMS2, MSH2, and MSH6) and p53, we stratified endometrial cancers into four molecular subtypes: POLE ultramutated, MMR-deficient, p53-mutant, and non-specific molecular profile (NSMP). PD-L1 was detected via immunohistochemistry and evaluated in tumor cells (TCs) and immune cells (ICs) individually and using the combined positive score (CPS). RESULTS: Positive PD-L1 staining in TCs (≥1%), ICs (≥1%), and in combination (CPS ≥1) was detected in 14.0%, 37.3%, and 45.1% of the samples, respectively. PD-L1 positivity in TCs was more frequent in high-grade than in low-grade tumors, while that in ICs was associated with lymphovascular space invasion, non-endometrioid histology, and deep myometrial invasion. PD-L1 expression in both TCs and ICs was more frequent in POLE ultramutated and MMR-deficient subtypes than in p53-mutant and NSMP subtypes. PD-L1 positivity in TCs, but not in ICs or combined (CPS), was associated with a favorable prognosis in patients with high-risk endometrial cancer. CONCLUSIONS: The distribution and prognostic significance of PD-L1 in TCs versus ICs differ in patients with endometrial cancer, indicating that the separate assessment of PD-L1 in these cells (rather than determining the CPS) may be more relevant to selecting patients eligible for endometrial cancer immunotherapy.
引用
- Zong L, Sun Z, Mo S, et al. PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer. Gynecol Oncol. 2021. PMID: 34272092. doi:10.1016/j.ygyno.2021.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。